A Multicenter Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer

Trial Profile

A Multicenter Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2017

At a glance

  • Drugs Lurbinectedin (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors PharmaMar
  • Most Recent Events

    • 02 Jun 2017 Results from this and one other study, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 19 May 2017 According to a PharmaMar media release, data from this trial will be presented at the 53rd Congress of the American Society of Clinical Oncology (ASCO) 2017.
    • 05 Jan 2017 Planned End Date changed from 1 Jun 2017 to 1 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top